UNC Lineberger awarded $11.9 million grant to study radiation treatments for prostate cancer
(UNC Lineberger Comprehensive Cancer Center) The Patient-Centered Outcomes Research Institute has awarded UNC Lineberger Comprehensive Cancer Center's Ronald C. Chen, MD, MPH, a five-year, nearly $12 million grant to fund a comparative study of intensity-modulated radiation therapy and proton beam for prostate cancer.
ConclusionsCoverage guidelines for IMRT, SRS, SABR, and PBT vary across 5 major insurance providers and may be substantially discordant compared with ASTRO coverage guidelines. There remain several specific areas where ongoing and future dialogues between ASTRO members, payers, and policymakers remain essential.
CONCLUSION: There is increasing variation among group practices in the use of conservative management for prostate cancer. This underscores the need for a better understanding of practice-level factors that influence prostate cancer management. PMID: 31509481 [PubMed - as supplied by publisher]
CONCLUSIONSCoverage guidelines for IMRT, SRS, SABR, and PBT vary across 5 major insurance providers and may be substantially discordant when compared to ASTRO coverage guidelines. There remain several specific areas where ongoing and future dialogue between ASTRO, payers, and policymakers remains essential.
ConclusionDifferent medical physicists or dosimetrists, photon energies, treatment planning systems, and treatment machines have an impact on the resulting dose distribution. However, the differences only become apparent when comparing DVH, analysing dose values, comparing CI, HI, GI, as well as reviewing the dose distribution in every single plane. A new score was introduced to identify treatment plans that simultaneously deliver a low dose to all OAR. Such inter- and intra-institutional comparison studies are needed to explore different treatment planning strategies; however, there is still no automatic soluti...
Abstract This work evaluated the use of a class solution specific calibration for an extra-large BaFBr based Optically Stimulated Luminescence film (OSL; 43x35cm²; Zeff =4.55). The clinical need for such large dosimeters follows from the increased use of extended-field radiation therapy (EFRT). E.g. for prostate cancer EFRT is currently used in the first prospective trial investigating the benefit of adding elective irradiation of the para-aortic lymph nodes in PN1 prostate cancer. The full extent of these EFRT dose distributions is not covered by the well-established standard sized radiochromic film or 2D de...
Three-dimensional conformal radiation therapy, intensity-modulated radiotherapy (IMRT), and volumetric-modulated arc radiotherapy (VMAT) are more effective curative treatment options for patients with localized adenocarcinoma of the prostate, compared with surgery [1 –2]. Gastrointestinal toxicity is the major treatment-related side effect in prostate cancer radiotherapy. The rates of acute and chronic grade (≥2) rectal toxicity increase by dose – increasing from 3 and 5%, to 20 and 21%, respectively [3–5].
Conclusions: A LASSO-based multivariable NTCP model comprising three important predictors (platelet count, risk group and V65) was established to predict the incidence of grade 2+ late rectal bleeding after IMRT.
CONCLUSION: Including PLNs in radiation fields for high-risk or locally advanced prostate cancer is not associated with increased GI or GU toxicity at 3 years. Additional follow-up is required to answer questions about its impact on late GU toxicity. Results from ongoing trials will provide insight into the anticancer effectiveness of PLN irradiation. PMID: 31163009 [PubMed - as supplied by publisher]
This study evaluated the efficacy of early initiation of salvage-ADT (S-ADT) based on predetermined timing among patients with unfavorable PCa treated with high-dose intensity-modulated radiation therapy (IMRT).Materials and methodsHigh-risk (HR) and very-high-risk (VHR) PCa patients treated with IMRT at our institution between September 2000 and December 2010 were analyzed retrospectively. Treatment consisted of high-dose IMRT (78 Gy/39 fractions) combined with 6 months of neoadjuvant-ADT (NA-ADT). S-ADT was initiated when prostate-specific antigen levels exceeded 4.0 ng/mL.ResultsIn total, 268 (184 ...
ConclusionSIB-IMRT using daily MV-CT guidance showed excellent long-term biochemical control and low toxicity rates.